Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2019 February;60(1) > The Journal of Cardiovascular Surgery 2019 February;60(1):8-13

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  RECENT DEVELOPMENTS IN THE MANAGEMENT OF CHRONIC TOTAL OCCLUSIONS 

The Journal of Cardiovascular Surgery 2019 February;60(1):8-13

DOI: 10.23736/S0021-9509.18.10787-7

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Endovascular treatment for the common femoral artery: is there a challenger to open surgery?

Koen DELOOSE 1 , Igor MARTINS 2, Caio NEVES 2, Joren CALLAERT 1

1 Department of Vascular Surgery, A.Z. Sint Blasius Hospital, Dendermonde, Belgium; 2 Department of Vascular Surgery, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil



Common femoral artery (CFA) atherosclerotic lesions currently remain one of the last limitations for adoption of endovascular repair as the first-line treatment. The bulky, eccentric, heavily calcified character of the CFA plaques, frequent involvement of the femoral bifurcation, easy surgical accessibility and last but not least, favorable long-term outcomes still make CFA disease treatment part of the surgical domain. In the last 5 years, improvement of the endovascular equipment and technical skills of the operators have led to an increase in percutaneous CFA procedures. Especially the vascular mimetic implant Supera Peripheral Stent system (Abbott Vascular), with its extreme crush resistance (if correctly implanted), seems to be an ideal tool to deal with eccentric calcified plaques, crush risk and maintaining access possibilities. The multicentric, prospective, single arm VMI-CFA Trial evaluates the outcome of treatment of symptomatic (Rutherford 2-4) CFA stenotic or occlusive lesions with the Supera Peripheral Stent System. A 6-month cumulative primary patency rate of 100% is noticed, up to 210 days. The cumulative freedom from TLR rate is 100%. Four patients died, not procedure or device related. From a clinical point of view, a tremendous switch from Rutherford 2-4 towards Rutherford 0-1 happened. No procedure nor device related adverse events are noticed. These short-term data confirm the safety and feasibility of an endovascular approach with the Supera stent to the “no-stent zone” CFA. Of course 12- and 24-month data are essential to bring more clarification in this interesting field.


KEY WORDS: Femoral artery - Endovascular procedures - Surgery

inizio pagina